Vermillion has appointed Thomas McLain as president and CEO. He replaces Bruce Huebner, who has served as interim CEO since last November when he took over for Gail Page.
Huebner will remain a director of the company.
Prior to joining Vermillion, McLain served as CEO and CFO of Claro Scientific. Before that, he held senior management positions at Nabi Biopharmaceuticals (now Biota Pharmaceuticals) and Bausch & Lomb. He has also served on the boards of Eastman Chemical, and the Biotechnology Industry Organization.
He holds an MBA in accounting and information systems from the University of Rochester, Simon Graduate School of Business, and a BA in economics from the College of the Holy Cross.